| Literature DB >> 30048805 |
Paul M Vespa1, Vikesh Shrestha2, Nicholas Abend3, Denes Agoston4, Alicia Au5, Michael J Bell6, Thomas P Bleck7, Manuel Buitrago Blanco2, Jan Claassen8, Ramon Diaz-Arrastia3, Dominique Duncan9, Ben Ellingson2, Brandon Foreman10, Emily J Gilmore11, Lawrence Hirsch11, Martin Hunn12, Alaa Kamnaksh4, David McArthur2, Andrew Morokoff13, Terrence O'Brien13, Kristine O'Phelan14, Courtney L Robertson15, Eric Rosenthal16, Richard Staba2, Arthur Toga9, Frederick A Willyerd17, Lara Zimmermann18, Elisa Yam2, Susana Martinez2, Courtney Real2, Jerome Engel2.
Abstract
The Epilepsy Bioinformatics Study for Anti-epileptogenic Therapy (EpiBioS4Rx) is a longitudinal prospective observational study funded by the National Institute of Health (NIH) to discover and validate observational biomarkers of epileptogenesis after traumatic brain injury (TBI). A multidisciplinary approach has been incorporated to investigate acute electrical, neuroanatomical, and blood biomarkers after TBI that may predict the development of post-traumatic epilepsy (PTE). We plan to enroll 300 moderate-severe TBI patients with a frontal and/or temporal lobe hemorrhagic contusion. Acute evaluation with blood, imaging and electroencephalographic monitoring will be performed and then patients will be tracked for 2 years to determine the incidence of PTE. Validation of selected biomarkers that are discovered in planned animal models will be a principal feature of this work. Specific hypotheses regarding the discovery of biomarkers have been set forth in this study. An international cohort of 13 centers spanning 2 continents will be developed to facilitate this study, and for future interventional studies.Entities:
Mesh：
Substances：
Year: 2018 PMID： 30048805 PMCID： PMC6344322 DOI： 10.1016/j.nbd.2018.07.025
Source DB: PubMed Journal: Neurobiol Dis ISSN： 0969-9961 Impact factor: 5.996